Monalisa Ghosh, MD, discusses the role of idecabtagene vicleucel in relapsed/refractory multiple myeloma landscape.
Monalisa Ghosh, MD, a clinical assistant professor at the University of Michigan, discusses the role ofidecabtagene vicleucel (ide-cel;Abecma) in relapsed/refractory multiple myeloma landscape.
The March 2021 FDA approval of ide-cel helped to add another tool to treat this patient population, which is a development has been largely beneficial, Ghosh says. For many patients, multiple myeloma is a chronic cancer without many treatment options in the relapsed/refractory setting, she adds.
Currently, there are many new experimental therapies in development for this patient population, and healthcare providers must figure out where CAR T-cell therapy fits into the landscape, as well as how to sequence it with other treatments, Ghosh says. Ongoing studies are examining CAR T-cell therapies earlier in the treatment course, as well as in different populations of patients with multiple myeloma, Ghosh notes. As of yet, it is not known how ide-cel could fit into the treatment lineup for myeloma, Ghosh concludes.